Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort.
Paul J ClarkPatricia Casarolli ValerySimone I StrasserMartin WeltmanAlexander J ThompsonMiriam LevyBarbara LeggettAmany ZekryJulian RongPeter AngusJacob GeorgeSteven BollipoBruce McGarityWilliam SievertGerry MacquillanEdmund TseAmanda NicollAmanda WadeGeoff ChuDamian HardingWendy ChengGeoff FarrellStuart K RobertsPublished in: Digestive diseases and sciences (2022)
Excellent SVR rates were achieved with DAAs in this real-world cohort of patients with chronic HCV infection. More advanced liver disease and clinician impression of poor adherence were associated with HCV treatment failure. Supports to improve liver fibrosis assessment skills for non-specialist DAA prescribers in the community and to optimize patient adherence are likely to enable more effective pursuit of HCV elimination in Australia.